Table 3 Investigational combinations and novel therapies in relapsed cHL

Nivo + ipilimumab

1b

31

74 [23]

NP^a

NR

(53)

Nivo + ipilimumab

1b

21

76 [24]

NP

NR

(53)

Nivo + ipilimumab + BV

1/2

64

82 [57]

1.7 years

NR

(54)

Nivo + ibrutinib

2

10

66 [44]

9.5 months

NR

(55)

Pembro + acalabrutinib

1b/2

161^c

–

–

–

NCT0236035

Cami-T

2

117

70.1 [33.3]

10.7 months

9.1 months

(63)

Pembro + favezelimab

1/2

33

31 [7]

16.5 months

9 months

(66)

CD30 CART

2

41

72 [59]

17.8 months

14.8 months^d

(69)

CD30 CART

2

97^c

–

–

–

NCT04268706

Anti-EBV directed cell therapy

2

25

61.9 [52.4]

NP

NP^e

(71)

Anti-EBV/DN TGF beta cell therapy

1

8

57.1 [28.6]

NP

NP

(72)

Anti-EBV/CD30 dual CART

1

18^c

–

⁻

⁻

NCT01192464